There are multiple challenges associated with trying to pursue precision medicine, explained Victoria Villaflor, MD, associate professor of Medicine, hematology and oncology, Northwestern University.
There are multiple challenges associated with trying to pursue precision medicine, explained Victoria Villaflor, MD, associate professor of Medicine, Hematology and Oncology, Northwestern University.
Transcript
What challenges are associated with trying to pursue precision medicine?
There are multiple challenges. We’ll start with the clinician. So, when the physician comes in to see the patient, there’s so much data that’s out there, and depending on the environment the physician is seeing the patient in also dictates some of this. A physician [who] has to know every single tumor type [is not] going to be able to keep up with the massive data and the studies and everything that’s coming out for every single tumor type. So, keeping up with the data, integrating it, being able to actually teach the patient about it, and implement[ing] it is one of the great challenges that is out there.
Other challenges are who should we be testing with this, what test should we be doing, and keeping the physician up-to-date with that. [On] the patient's end of things, the willingness to do some of the precision techniques, because they do take time, and also their expectations may be somewhat unrealistic. Things that you have to worry about is that the patient says, "Oh great, I have this mutation, I should be responding to X therapy,” or perhaps, “My tumor proportion score of PD-L1 is 80, I should have a great response to one of the checkpoint inhibitors,” and in fact they don’t.
Studies have shown, with most of these agents, response rates are somewhere in about 50 percentile, maybe 54 percentile. A couple actually go up into the 60 to 70 percentile. But, not everybody who should respond is responding, so the expectations can be unrealistic on both the clinicians and the patient standpoint.
As far as testing, that’s a whole other ball of wax. You know, we start out with how do we identify the patients that should be getting testing, and how do we identify, of those patients, who should be getting treatment and who shouldn’t. One of the early examples of this is the Oncotype Dx, which is used in breast cancer to determine patients who have undergone surgery with estrogen-receptor positivity who should be getting adjuvant chemotherapy. Well, that’s only 1 example. How do we pick out other patients who should be being treated and who shouldn’t be being treated?
Another example would be: how do we pick out who is going to respond. What test should we be doing? Should they be immunohistochemistry? Should they be fluorescence in situ hybridization type testing? Should it be something along the lines of next-generation sequencing? Nobody really knows the answer to that, and there are standardization issues, other issues that occur are: what toxicity tests should we be doing?
Other things could include who should be being tested for germline mutations. We usually determine that if a patient comes in and has many of their family members affected by cancer, but those are the only patients that, right now, we’re recommending have germline testing. Are there are other families that we are missing? Other germline mutations we really don’t know about yet?
So, I think overall, it’s a very complicated situation, and really determining which patients should get what tests and as to what patients should get what tests is complicated.
Now, when we get to treatment, what are the actual treatments we should be having? Some of it has been well worked out. A lot of it hasn’t been. The other thing is, we need to have well-developed molecular marker-driven clinical studies for patients to be enrolled in.
The other thing are the master protocols and getting patients to participate in that, and then what about those that are nonresponders. What do we do about them? How do we figure out what the heck is going on with them? So, overall, it’s a very complicated and complex problem.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More